Drug Trial Radar · NCT07218796
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 28, 2025
Primary completion
May 31, 2029
Study completion May 31, 2031
Sponsor
- Lead sponsor
- SpyGlass Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Conditions
- Cataract
- Glaucoma
- Ocular Hypertension
Interventions
Bimatoprost Implant SystemDrug
Bimatoprost Implant System used in combination with the SpyGlass IOL
SpyGlass IOLDevice
SpyGlass Intraocular Lens
Timolol Maleate Ophthalmic Solution, 0.5%Drug
Timolol Maleate Ophthalmic Solution, 0.5% BID
Commercial IOLDevice
Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean IOP Reduction from Baseline (mmHg)Time frame: Weeks 2 and 6, and Month 3
- BCDVA 20/40 or betterTime frame: Month 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
R and R Eye Research, LLC
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.